Tech Center 1600 • Art Units: 1621 1625
This examiner grants 81% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17990134 | ORGANIC COMPOUND AND SENSOR AND SENSOR EMBEDDED DISPLAY PANEL AND ELECTRONIC DEVICE | Non-Final OA | Samsung Electronics Co., Ltd. |
| 18279903 | PROCESS FOR PREPARING A MELAMINE CONDENSATION PRODUCT | Non-Final OA | BASF SE |
| 19312779 | TREATMENT OF A SELECTIVE POPULATION OF PATIENTS HAVING DEMENTIA WITH LEWY BODIES | Final Rejection | EIP Pharma, LLC |
| 18503009 | DOSING REGIMEN OF KRAS G12C INHIBITOR | Non-Final OA | AMGEN INC. |
| 18554345 | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING SAME | Non-Final OA | LG CHEM, LTD. |
| 18265337 | Compound And Organic Light Emitting Device Comprising The Same | Non-Final OA | LG Chem, Ltd. |
| 18573785 | COMPOSITION FOR SUPPRESSING MUSCLE DAMAGE | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18634083 | TETRADENTATE PLATINUM AND PALLADIUM COMPLEXES BASED ON BISCARBAZOLE AND ANALOGUES | Final Rejection | Arizona Board of Regents on behalf of Arizona State University |
| 18418800 | TETRADENTATE PLATINUM AND PALLADIUM COMPLEX EMITTERS CONTAINING PHENYL-PYRAZOLE AND ITS ANALOGUES | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 18393497 | EMITTERS BASED ON OCTAHEDRAL METAL COMPLEXES | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 18565799 | NOVEL XANTHONE COMPOUND HAVING EXCELLENT ANTICANCER EFFECT | Non-Final OA | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY |
| 18279290 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Non-Final OA | Mindset Pharma Inc. |
| 18412997 | CYCLOSILAZANE PRECURSORS AND RELATED METHODS | Non-Final OA | ENTEGRIS, INC. |
| 18171735 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | Non-Final OA | ASTRAZENECA AB |
| 18286291 | FLUORESCENT PROBE FOR USE IN DETECTION OF PANCREATIC CANCER | Non-Final OA | The University of Tokyo |
| 18264448 | PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18006197 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18558931 | ALKYLAMIDE SUBSTITUTED, ANNULATED IMIDAZOLES AND USE THEREOF AS INSECTICIDES | Non-Final OA | Bayer Aktiengesellschaft |
| 18279796 | PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | Non-Final OA | King's College London |
| 18022252 | METHODS OF NEUROPROTECTION AND USES THEREOF | Final Rejection | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION |
| 17919650 | TARGETING THE PALMOTYLATION/DEPALMOTYLATION CYCLE TO TREAT INFLAMMATORY DISEASES | Non-Final OA | CORNELL UNIVERSITY |
| 18740078 | QUINOLINE DERIVATIVES | Non-Final OA | Gilead Sciences, Inc. |
| 18264670 | THIENOPYRROLE COMPOUNDS | Non-Final OA | Gilead Sciences, Inc. |
| 18277637 | ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID | Final Rejection | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION |
| 18284236 | Managing the Acute and Long-Term Effects of Coronaviral Infections and Compositions Related Thereto | Non-Final OA | Children's Healthcare of Atlanta, Inc. |
| 18042314 | IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS | Non-Final OA | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED |
| 18550005 | Anti Viral Therapy | Non-Final OA | The Queen's University of Belfast |
| 18416590 | NOVEL SALTS OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | Final Rejection | InventisBio Co., Ltd. |
| 18394766 | INHIBITORS OF TRANSGLUTAMINASES | Non-Final OA | ZEDIRA GMBH |
| 18359955 | PREVENTION OR TREATMENT OF BRAIN DISEASE AND ADVERSE EFFECTS OF CHOLINESTERASE INHIBITORS | Non-Final OA | DR. NOAH BIOTECH INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy